Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while? / Støchkel Frank, Malene; Schou Nørøxe, Dorte; Nygård, Lotte; Fredberg Persson, Gitte.

I: BMC Palliative Care, Bind 17, Nr. 1, 2018, s. 15.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Støchkel Frank, M, Schou Nørøxe, D, Nygård, L & Fredberg Persson, G 2018, 'Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?', BMC Palliative Care, bind 17, nr. 1, s. 15. https://doi.org/10.1186/s12904-017-0270-4

APA

Støchkel Frank, M., Schou Nørøxe, D., Nygård, L., & Fredberg Persson, G. (2018). Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while? BMC Palliative Care, 17(1), 15. https://doi.org/10.1186/s12904-017-0270-4

Vancouver

Støchkel Frank M, Schou Nørøxe D, Nygård L, Fredberg Persson G. Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while? BMC Palliative Care. 2018;17(1):15. https://doi.org/10.1186/s12904-017-0270-4

Author

Støchkel Frank, Malene ; Schou Nørøxe, Dorte ; Nygård, Lotte ; Fredberg Persson, Gitte. / Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?. I: BMC Palliative Care. 2018 ; Bind 17, Nr. 1. s. 15.

Bibtex

@article{ee5c66bd6fec44eba353e5ed0a81af9e,

title = "Fractionated palliative thoracic radiotherapy in non-small cell lung cancer - futile or worth-while?",

abstract = "BACKGROUND: Palliative thoracic radiotherapy (PTR) can relieve symptoms originating from intra-thoracic disease. The optimal timing and fractionation of PTR is unknown. Time to effect is 2 months. The primary aim of this retrospective study was to investigate survival after PTR, hypothesizing that a significant number of patients received futile fractionated PTR. The secondary aim was to find prognostic factors to guide treatment decisions.METHODS: Patients with non-small-cell lung cancer (NSCLC) planned for PTR in the period of 2010-2011 at the University Hospital of Copenhagen were included. We noted pathology, tumor, node and metastasis (TNM) classification of malignant tumors, stage, indication, start date, schedule for PTR, completed y/n, performance status (PS) and time of death. Analyses were performed as an intention-to-treat using Cox regression, Fishers exact test and Kaplan Meier.RESULTS: A total of 159 patients were included. Median overall survival (OS) was 4.2 months. Sixteen patients (10%) did either not begin or finish PTR. Of these, eight (5%) died prior to or during PTR. Of the 151 patients receiving PTR, sixteen patients (11%) died within 14 days, thirty-three (22%) within 30 days and fifty (33%) within 2 months. PS 0-1 and squamous cell carcinoma were correlated with a better survival.CONCLUSIONS: Our study show that a significant number of patients who received PTR died before they could achieve optimal effect of the treatment. PS and histology were significant prognostic factors favoring PS 0-1 and squamous cell carcinoma. Based on our study, we suggest that patients with PS 0-1 should be considered for fractionated PTR whereas patients with PS ≥ 2 should be considered for high dose single fraction only or supportive palliative care.",

keywords = "Non-small-cell lung cancer, NSCLC, Overall survival, Palliative, Performance status, Ps, Radiotherapy, Thoracic",

author = "{St{\o}chkel Frank}, Malene and {Schou N{\o}r{\o}xe}, Dorte and Lotte Nyg{\aa}rd and {Fredberg Persson}, Gitte",

year = "2018",

doi = "10.1186/s12904-017-0270-4",

language = "English",

volume = "17",

pages = "15",

journal = "BMC Palliative Care",

issn = "1472-684X",

publisher = "BioMed Central Ltd.",

number = "1",